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Abstract High-grade osteosarcoma occurs predomi-
nantly in adolescents and young adults and has an overall
survival rate of about 60%, despite chemotherapy and
surgery. Therefore, novel treatment modalities are needed
to prevent or treat recurrent disease. Natural killer (NK)
cells are lymphocytes with cytotoxic activity toward virus-
infected or malignant cells. We explored the feasibility of
autologous and allogeneic NK cell–mediated therapies
for chemotherapy-resistant and chemotherapy-sensitive
high-grade osteosarcoma. The expression by osteosarcoma
cells of ligands for activating NK cell receptors was studied
in vitro and in vivo, and their contribution to NK cell–
mediated cytolysis was studied by speciﬁc antibody
blockade. Chromium release cytotoxicity assays revealed
chemotherapy-sensitive and chemotherapy-resistant osteo-
sarcoma cell lines and osteosarcoma primary cultures to be
sensitive to NK cell–mediated cytolysis. Cytolytic activity
was strongly enhanced by IL-15 activation and was
dependent on DNAM-1 and NKG2D pathways. Autolo-
gous and allogeneic activated NK cells lysed osteosarcoma
primary cultures equally well. Osteosarcoma patient–
derived NK cells were functionally and phenotypically
unimpaired. In conclusion, osteosarcoma cells, including
chemoresistant variants, are highly susceptible to lysis by
IL-15-induced NK cells from both allogeneic and autolo-
gous origin. Our data support the exploitation of NK cells
or NK cell–activating agents in patients with high-grade
osteosarcoma.
Keywords Osteosarcoma  Immunotherapy  NK cells 
Bone sarcoma
Introduction
High-grade osteosarcoma is the most common primary
malignant bone sarcoma, occurring mainly in adolescents
and young adults [1]. Despite multi-agent chemotherapy
and surgery, overall survival is still poor at about sixty
percent [2–4]. Therefore, novel treatment modalities are
urgently needed to either prevent or treat chemotherapy
refractory and recurrent disease. Immunomodulatory
agents such as interferon (IFN)-a and muramyl-tri-peptide
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DOI 10.1007/s00262-010-0965-3(MTP) have been added to standard chemotherapy regi-
mens in recent clinical trials [5–7]. Immunotherapy with
stimulatory cytokines such as IL-2 and IL-15 or the
adoptive transfer of ex vivo cytokine-activated cytotoxic
lymphocytes such as natural killer (NK) cells could be
another adjunct to current therapy [8–10].
NK cells lack a clonally rearranged antigen-speciﬁc
receptor. Instead, cytolytic activity toward virus-infected or
malignant cells is dependent on the balance between
inhibitory and activating signals. NK cell–activating sig-
nals are provided when the activating receptors Natural
Killer Group 2, member D (NKG2D), DNAX accessory
molecule-1 (DNAM-1), and the natural cytotoxicity
receptors (NCRs) NKp30, NKp44, and NKp46 bind their
respective ligands [11–13]. Although NK cell recognition
of tumor cells has been reported to be partially mediated
through NCRs, the responsible ligands are unknown [14].
The DNAM-1 ligands poliovirus receptor (PVR, CD155)
and Nectin-2 (CD112) are highly expressed by many
tumors, including sarcomas [13, 15, 16]. Ligands for
NKG2D are the stress-inducible major histocompatibility
class I polypeptide-related sequence (MIC) A and B and
the UL-16-binding proteins (ULBPs) 1–4. Inhibitory
ligands are the classical and non-classical human leukocyte
antigen (HLA) class I molecules expressed on all normal
cells [17]. These ligands bind to inhibitory killer immu-
noglobulin receptors (KIRs) and the C-type lectin hetero-
dimer CD94/NKG2A on NK cells, respectively. In addition
to high expression of NKG2D and DNAM-1 ligands, many
tumors show loss of HLA class I, possibly rendering them
susceptible to NK cell–mediated lysis [18, 19].
In the current study, we demonstrated the sensitivity of
chemotherapy-resistant and chemotherapy-sensitive osteo-
sarcoma cells to lysis by IL-15-activated NK cells and
identiﬁed the molecular mechanisms involved. NK cells of
osteosarcoma patients were not functionally impaired and
were able to lyse autologous tumor cells, supporting the use
of NK cell–activating agents in the treatment of osteosar-
coma patients.
Materials and methods
Patient material
Atissuearraywasconstructedfromformalin-ﬁxed,parafﬁn-
embedded (FFPE) tissue retrospectively collected from 88
osteosarcoma patients treated at the LUMC as previously
described [20] (Suppl. Table 1). Peripheral blood mononu-
clear cells (PBMCs) were collected from healthy controls
and 22 pre-treatment osteosarcoma patients after written
informed consent was obtained, as approved by the Institu-
tional Review Board on Medical Ethics. Osteosarcoma
tissue samples were used for research in accordance with
national ethical guidelines (Code for Proper Secondary Use
of Human Tissue, Dutch Federation of Medical Scientiﬁc
Societies). All patient material was handled in a coded
fashion. Clinical and pathological details of all patients can
be found in Suppl. Table 2.
Cell lines and primary cultures
The osteosarcoma cell lines HOS, 143B/HOS, IOR-OS14,
SJSA-1, OHS, ZK-58, U2-OS, and SAOS-2 were charac-
terized and maintained as described earlier [21]. The EBV
B-LCLcellline107(EBV)andtheerythroleukemiccellline
K562 were maintained in RPMI 1640 medium (Invitrogen,
Carlsbad, CA) supplemented with 10% fetal calf serum
(FCS, Invitrogen) and 1% penicillin/streptomycin (PS,
Invitrogen). The chemotherapy-resistant variant cell lines of
U2-OS and SAOS-2 were established as described previ-
ously [22–24] and were maintained in Iscove’s modiﬁed
Dulbecco’s medium (IMDM, Invitrogen) supplemented
with 10% FCS and PS. The doxorubicin (DX)-resistant
variants U2-OS-DX580 and SAOS-2-DX580 were cultured
inthepresence of580 lg/mlDX.Themethotrexate(MTX)-
resistant variants U2-OS-MTX300 and SAOS-2-MTX1 lg
were cultured in the presence of 300 and 1,000 ng/ml MTX,
respectively. The cisplatin (cis-diamminedichloroplatinum,
CDDP)-resistant variants U2-OS-CDDP4 lg and SAOS-
2CDDP6 lg were cultured in the presence of 4 and 6 lg/ml
CDDP, respectively.
Fresh osteosarcoma samples L2808, L2599, L2792,
L2635, and L2531 were cultured as described previously by
our group for related tumors [25]. Clinical and histopa-
thological details can be found in Suppl. Table 3. L2531,
L2792, and L2599 were derived from patients with poor
histological response to pre-operative chemotherapy in the
primary tumor. L2808, a pulmonary metastatic sample, was
derived from a patient with good histological response in
the primary tumor but who relapsed nonetheless. L2635
originated from a patient with good histological response
to pre-operative chemotherapy who is currently in persis-
tent ﬁrst complete remission (follow-up since diagnosis
20 months). Collected tissue pieces were dissociated
mechanically and cultured in RPMI 1640 medium supple-
mented with 20% FCS and PS. When subconﬂuence was
reached, cells were harvested using 0.05% Trypsin/EDTA
(Invitrogen) and passaged. Chromium release assays and
ﬂow cytometric analyses were performed no later than at
passage 3.
Isolation and culture of NK cells
PBMCs were isolated using a Ficoll density gradient sep-
aration followed by NK cell enrichment using the MACS
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123NK enrichment kit and LS columns (Miltenyi Biotec,
Bergisch Gladbach, Germany) according to the manufac-
turer’s protocol. Purity of NK cells was assessed by ﬂow
cytometry and was typically around 95% (less than 1% T
cells). NK cells were cultured in AIM-V medium (Invit-
rogen), supplemented with 10% pooled human AB serum
(Sanquin, Rotterdam, the Netherlands), PS and glutamine
(Glutamax I, Invitrogen). Activated NK cells were cultured
with 10 ng/ml recombinant human interleukin-15 (IL-15)
for 3 days or 2 weeks (Peprotech, Rocky Hill, NJ).
Flow cytometry
Surface staining of cells for ﬂow cytometry was performed
as described elsewhere [18]. Intracellular ﬂow cytometry
staining was done using permeabilization and ﬁxation kits
as per manufacturer’s instructions (00-5123; 00-5223;
00-8333, eBioscience, San Diego, CA). An overview of
antibodies can be found in Suppl. Table 4. Flow cytometry
of PBMC of osteosarcoma patients and healthy controls
was performed on a BD LSRII and analyzed using FACS
Diva Software 5.0 (both from Becton-Dickinson, San
Diego, CA). Mean ﬂuorescence intensity (MFI) of cell
subsets was calculated by subtracting the MFI of a negative
population from the MFI of the population of interest
within one individual to correct for interindividual vari-
ability of background staining. Flow cytometry of cell lines
and puriﬁed NK cells was performed on a FACScalibur and
analyzed using Cellquest software (both Becton-Dickin-
son). MFI ratio was calculated by MFI of the speciﬁc
staining relative to the MFI of the appropriate isotype
control staining.
Immunohistochemistry
Immunohistochemistry was performed on FFPE tissue
array sections as previously described [20]. Testis was used
as a positive control for the activating NK ligands and
tonsil for the inhibitory ligands. Sections were blocked
using 10% swine or goat serum in PBS and subsequently
incubated with primary antibody diluted in 0.5% bovine
serum albumin (BSA) in PBS overnight. As a negative
control, 0.5% BSA/PBS without primary antibody was
used. All primary antibodies are listed in Suppl. Table 4.
Anti-rabbit/rat/mouse PowerVision Poly-HRP (Leica Bio-
systems, Newcastle Upon Tyne, United Kingdom) was
used as a secondary antibody, except for the MICA stain-
ing, in which case the Universal LSAB? Kit (DAKO,
Glostrup, Denmark) was used. DAB? (DAKO) was used
as a chromogen. Sections were counterstained using
Mayer’s hematoxylin. Tissue array images were acquired
using the MIRAX slide scanner (3DHISTECH, Budapest,
Hungary) and analyzed using the MIRAX viewer version
1.14 (3DHISTECH). Slides were scored by two observers
(EPB and PCWH) in a modiﬁed semi-quantitative scoring
system as proposed by Ruiter et al. [26]. The intensity of
staining was scored as 0, 1, 2, or 3 indicating absent, weak,
clear, or strong expression, respectively. Percentages of
positive cells were scored as 0 for 0%, 1 for 1–30%, 2 for
31–70%, and 3 for 71–100%.
Chromium release assays
Cytotoxicity was determined in standard 4-h Chromium
release assays. For experiments using PBMCs of OS
patients and controls, PBMCs were thawed from storage in
liquid nitrogen and allowed to recover for 16 h in RPMI
1640 supplemented with 10% FCS and PS. The E:T ratios
in these experiments were corrected for the percentage of
NK cells of PBMCs as determined by ﬂow cytometry. For
all other experiments, puriﬁed unstimulated or IL-15-acti-
vated NK cells were used as effector cells. Target cells
(cell lines or primary cultures) were incubated with
100 lCi sodium-51-chromate (PerkinElmer, Wellesley,
MA) for 1 h. Effector cells (PBMCs, unstimulated puriﬁed
NK cells, or activated NK cells) were incubated for 4 h
with 2,500 target cells at eight effector:target (E:T) ratios
in triplicate. Maximum and spontaneous release was
determined by incubating targets in 2 N HCl or medium,
respectively. Supernatants were harvested and measured in
a gamma-counter (Wallac, PerkinElmer). Speciﬁc lysis
was determined as: (experimental release-spontaneous
release)/(maximum release-spontaneous release) 9 100%.
In all NK cytotoxicity experiments, K562 and EBV were
used as positive and negative controls, respectively. For
blocking experiments, NK cells were pre-incubated with
blocking anti-NKG2D (R&D systems, clone 149810) and/
or blocking anti-DNAM-1 (BD Pharmingen, clone DX11)
at a concentration of 20 lg/ml. To disrupt perforin/gran-
zyme–mediated cytolysis, NK cells were pre-incubated for
2 h at 37C with or without 1 lM Concanamycin A
(Sigma-Aldrich, Zwijndrecht, the Netherlands) prior to
adding the NK cells to the target cells. To block
Fas-induced apoptosis, target cells were pre-incubated with
2 lg/ml neutralizing anti-Fas antibody (Clone ZB4,
Millipore, Temecula, CA).
Statistical analysis
Statistical analyses were performed using GraphPad Prism
5.0 (LaJolla, CA). Data with non-normal distribution or
small sample size were analyzed using non-parametric
methods (Mann–Whitney U, Kruskal–Wallis, Friedman,
and Dunn’s tests), and data with normal distribution were
analyzed using parametric methods (t tests, one-way
analysis of variance (ANOVA), and Bonferroni’s tests).
Cancer Immunol Immunother (2011) 60:575–586 577
123Survival analyses were performed using Kaplan–Meier
curves and compared using the logrank method.
Results
Osteosarcoma cells are highly susceptible
to IL-15-activated allogeneic NK cells
We tested eight osteosarcoma cell lines for susceptibility to
cytolytic activity of freshly isolated (‘unstimulated’) and
IL-15-cultured (‘activated’) healthy donor-derived NK
cells. All cell lines were lysed by unstimulated allogeneic
NK cells at levels comparable to the positive control cell
line K562 (Fig. 1a and b). Cytolysis of all osteosarcoma
cell lines was strongly enhanced when IL-15-cultured
allogeneic NK cells were used.
Osteosarcoma cells express inhibitory and activating
NK cell ligands
Osteosarcoma cells expressed activating NK cell ligands
and HLA class I, both in vivo and in vitro (Table 1 and
Fig. 2). All osteosarcoma cell lines expressed HLA class I,
at least 3/5 NKG2D ligands and both DNAM-1 ligands.
Expression of ligands in vivo was determined on the tissue
array containing 144 samples of 88 patients. In chemo-
therapy-naive tumor material MICA, DNAM-1 ligands and
HLA class I were also expressed, albeit at different levels
(Fig. 2a). In tumor cells persisting after chemotherapy,
levels of MICA, HLA class I, and b-2 microglobulin
expression were unaltered but the expression levels of the
DNAM-1 ligands CD112 and CD155 were signiﬁcantly
decreased (Fig. 2b). There was a trend for patients with
high (score[4) versus low (score B 4) expression of
MICA in pre-treatment diagnostic biopsies to have better
overall survival (n = 53, P-value logrank test = 0.07).
Expression level of HLA class I in diagnostic biopsies as
determined by staining with antibodies recognizing b-2
microglobulin, HLA-A, and HLA-B/C did not correlate
with tumor progression.
NK cells lyse osteosarcoma cells
in a DNAM-1- and NKG2D-dependent manner
NK cell–mediated cytolysis of osteosarcoma cells was
dependent on NKG2D and DNAM-1 pathways, as was
demonstrated by blocking DNAM-1, NKG2D, or both
receptors (Fig. 3). In resting NK cells, the DNAM-1
pathway appeared to predominate the cytolytic potential,
whereas the contribution of the NKG2D pathway was more
prominent in the cytolytic activity of IL-15-cultured NK
cells. In case of IL-15-cultured NK cells, blockade of both
pathways was required for the optimal inhibition of NK
cytolytic activity. Levels of expression of HLA class I did
not correlate with magnitude of lysis by unstimulated or
IL-15-activated NK cells. Similarly, levels of expression of
ligands for the activating receptors NKG2D or DNAM-1
did not correlate with degree of lysis by NK cells (data not
shown).
b a
Fig. 1 Osteosarcoma cells were sensitive to lysis by freshly isolated
NK cells (solid lines) and NK cells cultured in IL-15 for 2 weeks
(dashed lines). a examples of percentage of speciﬁc lysis are shown
for the osteosarcoma cell lines SAOS-2 (ﬁlled circle), 143B/HOS
(open circle), IOR/OS-14 (ﬁlled square), and ZK-58 (open square).
Cell lines were incubated with increasing numbers of NK cells (E:T;
effector to target ratio). Error bars represent standard error of the
mean lysis of a representative experiment performed in triplicate.
b mean percentage of speciﬁc lysis by unstimulated (white bars) and
IL-15-activated (black bars) NK cells of the osteosarcoma cell lines
143B/HOS, SJSA-1, OHS, U2-OS, SAOS-2, IOR/OS-14, HOS, and
ZK-58 at an effector to target ratio of 10:1. Error bars represent
standard error of the mean of independent experiments using different
healthy donor NK cells. Numbers in the bars represent number of
experiments. K562 and an EBV-transformed B-LCL (‘‘EBV’’) were
used as positive and negative controls, respectively. Mann–Whitney
U test was done comparing IL-15-activated NK cells with unstim-
ulated NK cells for each cell line; P-value\0.05 noted as
*;\0.01 as **;\0.001 as ***
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MICA CD112 CD155
MICA   CD112 CD155 HLA class I
a
b
c
Fig. 2 a Examples of immunohistochemical staining of ligands for
the activating receptors NKG2D (MICA) and DNAM-1 (CD112 and
CD155) and of b2-microglobulin, HLA-A (HCA2), and HLA-B/C
(HC10) on osteosarcoma samples. b Overview of the results of
immunohistochemical stainings on pre-chemotherapy and post-che-
motherapy samples of the primary tumor as well as metastatic
osteosarcoma tissue. Expression levels of CD112 and CD155 but not
the other ligands decreased signiﬁcantly upon chemotherapy treat-
ment (P-value Kruskal–Wallis test \0.001 as ***). c Example of
ﬂow cytometry plots for MICA, CD112, CD155, and HLA class I for
the osteosarcoma cell line IOR/OS-14; isotype-matched control
staining is shown in gray
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123Chemotherapy-resistant osteosarcoma cells remain
sensitive to lysis by IL-15-activated NK cells
To study whether chemotherapy-resistant cell lines have
become resistant to NK cell–mediated lysis as well, the
sensitivity of a panel of chemotherapy-resistant variants of
the osteosarcoma cell lines SAOS-2 and U2-OS (selected
in vitro to be resistant to DX, CDDP or MTX) to lysis by
NK cells was tested (Fig. 4a). Although some SAOS
variants, e.g., CDDP, were less sensitive to lysis by resting
NK cells, activation of NK cells with IL-15 greatly
enhanced the lysis of all U2-OS and SAOS-2 chemother-
apy-resistant variant cell lines (Fig 4a). Expression levels
of NKG2D and DNAM-1 ligands were similar in chemo-
therapy-resistant variants and parental cell lines, as was the
dependency on NKG2D and DNAM-1 signaling in cyto-
toxicity assays (Table 1 and Suppl. Fig. 1). Expression
levels of HLA class I and of the adhesion molecules
ICAM-1 and LFA-3 were unaltered in the chemotherapy-
resistant variants, but expression of CD95 (death receptor
Fas) was lost in the SAOS-2 CDDP- and DX-resistant
variants (Table 1 and Fig. 4b). Since the loss of CD95
could provide an explanation for reduced susceptibility to
NK cell–induced lysis, we performed blocking experiments
in which both CD95 and the granule exocytosis pathway
were blocked with a blocking antibody and Concanamycin
A, respectively. These experiments were performed using
IL-15-activated NK cells at an effector to target ratio of
40–1. Blocking the GrB but not the CD95 cytolytic path-
way almost completely abrogated NK cytolytic potential,
demonstrating the predominance of the granzymeB path-
way in NK cell–mediated lysis of parental as well as
CDDP-resistant variants of osteosarcoma cells (Fig. 4c).
Similar results were obtained when the U2-OS parental cell
line was used (data not shown).
Peripheral blood NK cell phenotype is unaltered
and cytolytic potential is unimpaired in newly
diagnosed osteosarcoma patients
Since peripheral NK cells in patients with other tumor
types show altered phenotype and function, we analyzed
a
b
c
Fig. 3 a cytolysis of U2-OS by unstimulated (solid lines) and IL-15-
activated (dashed lines) NK cells was almost completely abrogated
when the NK cells were pre-incubated with both anti (a)-DNAM-1-
and a-NKG2D-blocking antibodies (ﬁlled square vs. open square).
Unstimulated NK cells were most dependent on DNAM-1 (open
circle) signaling, whereas activated NK cells were most dependent on
NKG2D (ﬁlled circle). Error bars represent standard error of the
mean lysis of experiment performed in triplicate. Similar results were
obtained for SAOS-2, HOS, and ZK-58 using unstimulated (b) and
IL-15-activated NK cells (c). Bars represent mean lysis in at least
three independent experiments using healthy donor NK cells; error
bars represent standard error of the mean. Friedman test, Dunn’s post-
test compared to non-blocked; P-value\0.05 noted as *; \0.01 as
**;\0.001 as ***
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123PBMCs of 22 newly diagnosed osteosarcoma patients and
23 age-matched healthy controls by ﬂow cytometry for NK
cell number and phenotype (Suppl. Fig. 2a). NK cell
number and phenotype were comparable between patients
and controls (Fig. 5a and Suppl. Fig. 2b and c). Following
3 days of culture in IL-15, there was a larger increase in
NKG2D and granzyme B expression levels on both
CD56dim and bright NK cells of osteosarcoma patients
than of healthy controls (Fig. 5a and Suppl. Fig. 2c). We
assessed the functionality of NK cells of osteosarcoma
patients at diagnosis in cytotoxicity assays using unstimu-
lated and 3 days IL-15-activated PBMCs as effector cells.
Resting NK cells from osteosarcoma patients and healthy
donors lysed the allogeneic target HOS equally well
(Fig. 5b), but IL-15-cultured NK cells of patients lysed
HOS signiﬁcantly better than healthy donor NK cells
(ANOVA, Bonferroni’s post-test P-value\0.0001). Per-
centage speciﬁc lysis of HOS correlated with the level of
NKG2D expression on CD56 dim NK cells (Fig. 5c;
Pearson correlation efﬁcient r
2 0.45, P-value\0.0001),
and similar results were obtained for the correlation with
granzyme B expression (not shown). To test whether the
functional integrity of NK cells from osteosarcoma patients
was also preserved toward autologous tumor cells, we took
advantage of the fact that we were able to derive short-term
cultured cells from fresh biopsies. Autologous, patient-
derived NK cells lysed short-term cultured tumor cells to a
similar degree as allogeneic NK cells from healthy controls
(Fig. 5d). In all cases, culture of both autologous and
allogeneic NK cells in IL-15 resulted in greatly enhanced
tumor cell killing.
Discussion
ThereisincreasinginterestinthepotentialforNKcellstobe
usedinthetreatmentofpediatricsolidtumors[27].Previous
studies have shown that osteosarcoma cell lines may be
sensitive to cytokine-activated NK cell–mediated cytotox-
icity [28–36]. However, little is known about the mecha-
nisms involved or the extent to which short-term cultured or
chemotherapy-resistant osteosarcoma cells are susceptible
to NK cell–mediated lysis. In addition, there is some evi-
dence for NK cell–mediated antiosteosarcoma activity in
vivo. Post-operative osteomyelitis-associated inhibition of
tumorgrowthwas dependent onthe activation ofmonocytes
and NK cells in a murine osteosarcoma model [37]. In
human osteosarcoma, treatment with interleukin (IL)-2 in a
smallcohortofpatientsresultedinNKcellactivation,which
was correlated with better clinical outcome [38]. Together,
these studies suggest that exploitation of NK cell activity
may be a suitable therapeutic tool in the adjuvant treatment
of osteosarcoma. In the present study, we demonstrate that
a
c
CD95
b
Fig. 4 a Lysis of U2-OS variants resistant to doxorubicin (DX),
methotrexate (MTX), or cisplatinum (CDDP) was comparable to lysis
of the parental control. The SAOS-2 CDDP-resistant line was less
sensitive to lysis by unstimulated NK cells than its parental control
(Friedman test P-value = 0.001 and Dunn’s post-test compared to
parental cell line P-value\0.001). NK cell activation (‘‘IL-15?’’)
increased lysis in all cases. Error bars represent standard error of the
mean lysis in at least six independent experiments. b SAOS-2
expressed the death receptor CD95 (Fas; black line), whereas
expression was lost in the cisplatinum-resistant variant of SAOS-2
(dashed line). Isotype-matched control staining is shown in gray. c the
granzyme/perforin pathway was the main cytotoxic pathway by which
NK cells lysed SAOS-2 and its chemotherapy-resistant variants, as
shown by inhibition of granule exocytosis by concanamycin A.
Blocking Fas resulted in a further decrease in the lysis of SAOS-2, but
not of the chemotherapy-resistant variants. Bars represent mean lysis
of experiment performed in triplicate; error bars represent standard
error of the mean. Similar results were obtained using NK cells from
another donor
582 Cancer Immunol Immunother (2011) 60:575–586
123osteosarcoma cells are highly susceptible to NK cell–med-
iated cytolysis (Fig. 1). Osteosarcoma cells expressed acti-
vating NKG2D and DNAM-1 ligands in vivo as well as in
vitro, and lysis was dependent on the interaction between
these ligands on osteosarcoma cells and their receptors on
NK cells (Figs. 2 and 3). Despite expression of the poten-
tially inhibitory KIR ligand HLA class I by osteosarcoma
cells, all cell lines and short-term cultures were highly
sensitive to lysis by IL-15-activated NK cells (Table 1 and
Figs. 1and5d).Together,thesedatasuggestthatthebalance
between expression of activating and inhibitory ligands in
osteosarcoma is shifted toward activation.
To investigate whether NK cell–based immunotherapy
is also feasible for patients with chemotherapy-resistant
disease, we tested the susceptibility of in vitro selected
chemotherapy-resistant osteosarcoma cells to NK cell–
mediated lysis. Methotrexate (MTX)-, doxorubicin (DX)-,
or cisplatin (CDDP)-resistant variants of the cell lines
SAOS-2 and U2-OS remained sensitive to lysis by IL-15-
activated NK cells (Fig. 4a). NK cells kill their targets by
the release of perforin and granzyme containing granules
and by the ligation of death receptors such as CD95 (Fas)
[39, 40]. Expression of CD95 was lost in the CDDP- and
DX-resistant SAOS-2 variants (Table 1 and Fig. 4), but
dual blocking studies demonstrated only a minor role of
Fas ligation in the lysis of osteosarcoma by cytokine-acti-
vated NK cells. Expression of Fas is frequently lost in
osteosarcoma pulmonary metastases, but our data show
that this will probably not hinder NK cell–based immu-
notherapeutic approaches [41–43].
b ac
d
Fig. 5 a NKG2D level was similar in unstimulated NK cells of
newly diagnosed osteosarcoma patients and healthy controls. Fol-
lowing culture for 3 days in IL15, there was a larger increase in the
expression level of NKG2D in NK cells of patients. b Unstimulated
PBMCs of 12 of 22 patients and 16 of 23 healthy controls and IL-15-
activated PBMCs of 19 of 22 patients and 17 of 23 controls were
available for functional testing. NK cells of newly diagnosed
osteosarcoma patients and of healthy controls lysed HOS at similar
levels. Following IL-15 activation, NK cells of osteosarcoma patients
showed a larger increase in cytotoxic activity than NK cells of healthy
donors. c cytotoxicity of IL-15-activated NK cells correlated with
level of NKG2D expression on the CD56dim subset (Pearson
correlation coefﬁcient). d primary osteosarcoma cell cultures were
tested for sensitivity to lysis by autologous (open circle) and
allogeneic (closed circle) NK cells. NK cells were unstimulated
(solid lines) or 3 days IL-15 activated (dashed lines). Autologous IL-
15-activated NK cells were available for all patients except L2792.
One-way analysis of variance (ANOVA) P-value\0.0001 for a, b,
and c. Bonferroni’s multiple comparison post-test; P-value\0.05
noted as *;\0.01 as **;\0.001 as ***
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123Studies on the feasibility of immunotherapeutic strate-
gies in bone tumors are often hampered by the technical
difﬁculty to isolate viable fresh tumor cells for functional
testing. To circumvent this problem, we used short-term
cultured cells. Susceptibility to NK cell–mediated lysis was
determined no later than at passage three. Four out of ﬁve
cultures originated from patients with chemotherapy-
resistant disease (L2531, L2792, L2599, and L2808). Still,
all were highly sensitive to lysis by cytokine-activated
autologous and allogeneic NK cells (Fig. 5d). Importantly,
our experiments on in vitro selected chemotherapy-resis-
tant cells and on short-term cell cultures generated from
patients with chemotherapy-resistant disease in vivo show
that IL-15-activated NK cells are capable of lysis of oste-
osarcoma cells resistant to chemotherapeutic agents com-
monly used in high-grade osteosarcoma treatment.
In many tumor types, including Ewing sarcoma, host
immune cells have decreased functionality when compared
with healthy donor cells [13, 44, 45]. In these cases, using
allogeneic immune cells instead of autologous cells is an
attractive option to increase efﬁcacy. However, it also
increases the risk of serious complications such as graft-
versus-host-disease. Our data show that NK cells of oste-
osarcoma patients are as potent as NK cells of healthy
controls in lysing osteosarcoma cells. Remarkably, upon
activation with IL-15, patient-derived NK cells even
showed a larger increase in the expression of NKG2D and
granzymeB than healthy donor–derived NK cells, which
correlated with an increased lysis of the osteosarcoma cell
line HOS (Fig. 5a and Suppl. Fig. 2c). This, and the lysis
of autologous tumor cells by ex vivo IL-15-activated NK
cells, indicates that immunotherapeutic strategies employ-
ing activated autologous NK cells could be as successful as
allogeneic NK cells in the treatment of osteosarcoma. In
preclinical validation studies, we obtained evidence that
IL15- and IL2-stimulated NK cells have similar cytolytic
activity against various tumor cell lines [46].
In conclusion, chemotherapy-resistant and chemother-
apy-sensitive osteosarcoma cells were lysed at high levels
by NK cells, particularly when NK cells were cytokine-
activated. Lysis of osteosarcoma cells was dependent on
DNAM-1 and NKG2D, ligands of which were expressed
by osteosarcoma cells both in vivo and in vitro. In contrast
to what has been reported in patients with other tumor
types, there was no intrinsic functional NK cell defect that
could hamper antitumor activity. Our study shows a
potential beneﬁt of either activating NK cells in vivo by the
administration of cytokines or adoptive transfer of ex vivo
activated autologous or allogeneic NK cells in the treat-
ment of high-grade osteosarcoma.
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